Lataa...
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigila...
Tallennettuna:
| Julkaisussa: | Clin Transl Radiat Oncol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369349/ https://ncbi.nlm.nih.gov/pubmed/32715108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctro.2020.06.013 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|